☰

Hiroyuki Seimiya - Publications

Affiliations: 
Molecular Biotherapy, Cancer Chemotherapy Japanese Foundation for Cancer Research, Japan 
Website:
http://read.jst.go.jp/public/cs_ksh_008EventAction.do?action4=event&lang_act4=E&judge_act4=2&knkysh_name_code=5000101957
Tree Info Similar researchers PubMed Report error

83/134 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Seimiya H, Nagasawa K, Shin-Ya K. Chemical targeting of G-quadruplexes in telomeres and beyond for molecular cancer therapeutics. The Journal of Antibiotics. PMID 34285374 DOI: 10.1038/s41429-021-00454-x  0.308
2020 Suenaga M, Mashima T, Kawata N, Wakatsuki T, Dan S, Seimiya H, Yamaguchi K. Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. International Journal of Colorectal Disease. PMID 32920703 DOI: 10.1007/S00384-020-03748-Y  0.315
2020 Seimiya H. Crossroads of telomere biology and anticancer drug discovery. Cancer Science. PMID 32579791 DOI: 10.1111/Cas.14540  0.449
2020 Tomizawa F, Jang MK, Mashima T, Seimiya H. c-KIT regulates stability of cancer stemness in CD44-positive colorectal cancer cells. Biochemical and Biophysical Research Communications. PMID 32439168 DOI: 10.1016/J.Bbrc.2020.05.024  0.374
2020 Nakanishi C, Seimiya H. G-quadruplex in cancer biology and drug discovery. Biochemical and Biophysical Research Communications. PMID 32312519 DOI: 10.1016/J.Bbrc.2020.03.178  0.359
2020 Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, ... ... Seimiya H, et al. Design and Discovery of an Orally Efficacious Spiroindolinone-based Tankyrase Inhibitor for the Treatment of Colon Cancer. Journal of Medicinal Chemistry. PMID 32202790 DOI: 10.1021/Acs.Jmedchem.0C00045.S002  0.378
2020 Kawakami R, Mashima T, Kawata N, Kumagai K, Migita T, Sano T, Mizunuma N, Yamaguchi K, Seimiya H. ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer. Cancer Science. PMID 31960523 DOI: 10.1111/Cas.14316  0.438
2020 Jang MK, Mashima T, Seimiya H. Tankyrase inhibitors target colorectal cancer stem cells via AXIN-dependent downregulation of c-KIT tyrosine kinase. Molecular Cancer Therapeutics. PMID 31907221 DOI: 10.1158/1535-7163.Mct-19-0668  0.431
2020 Suenaga M, Mashima T, Kawata N, Wakatsuki T, Seimiya H, Yamaguchi K. Circulating IL-8 levels as candidate marker of antiangiogenic therapy for metastatic colorectal cancer. Journal of Clinical Oncology. 38: 172-172. DOI: 10.1200/Jco.2020.38.4_Suppl.172  0.343
2019 Okamoto K, Seimiya H. From the wings to the center stage of chromosomes. The Journal of Biological Chemistry. 294: 17723-17724. PMID 31757801 DOI: 10.1074/Jbc.H119.011587  0.336
2019 Mashima T, Iwasaki R, Kawata N, Kawakami R, Kumagai K, Migita T, Sano T, Yamaguchi K, Seimiya H. In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells. British Journal of Cancer. PMID 31607750 DOI: 10.1038/S41416-019-0600-9  0.39
2019 Shirai F, Tsumura T, Yashiroda Y, Yuki H, Niwa H, Sato S, Chikada T, Koda Y, Washizuka K, Yoshimoto N, Abe M, Onuki T, Mazaki Y, Hirama C, Fukami T, ... ... Seimiya H, et al. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors. Journal of Medicinal Chemistry. PMID 30883102 DOI: 10.2210/Pdb5Zqr/Pdb  0.387
2019 Okamoto K, Seimiya H. Revisiting Telomere Shortening in Cancer. Cells. 8. PMID 30709063 DOI: 10.3390/Cells8020107  0.446
2018 Okamoto K, Ohishi T, Kuroiwa M, Iemura SI, Natsume T, Seimiya H. MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs. Oncotarget. 9: 35844-35855. PMID 30533199 DOI: 10.18632/Oncotarget.26312  0.388
2018 Fujiwara C, Muramatsu Y, Nishii M, Tokunaka K, Tahara H, Ueno M, Yamori T, Sugimoto Y, Seimiya H. Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells. Scientific Reports. 8: 14827. PMID 30287851 DOI: 10.1038/S41598-018-33139-X  0.445
2018 Mizutani A, Yashiroda Y, Muramatsu Y, Yoshida H, Chikada T, Tsumura T, Okue M, Shirai F, Fukami T, Yoshida M, Seimiya H. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Science. PMID 30238564 DOI: 10.1111/Cas.13805  0.418
2018 Suenaga M, Mashima T, Kawata N, Dan S, Wakatsuki T, Shinozaki E, Ichimura T, Ogura M, Takahari D, Osumi H, Ota Y, Chin K, Seimiya H, Yamaguchi K, Yamaguchi T. Identification of biomarkers for TAS-102 efficacy in metastatic colorectal cancer patients based on preclinical analysis and clinical validation. Journal of Clinical Oncology. 36: 669-669. DOI: 10.1200/Jco.2018.36.4_Suppl.669  0.366
2018 Okabe S, Nakamura T, Hasegawa D, Kojima R, Okamoto K, Nakano I, Shin-ya K, Nagasawa K, Seimiya H. Abstract 4839: Targeting glioma stem cells by pharmacologic stabilization of G-quadruplexes Cancer Research. 78: 4839-4839. DOI: 10.1158/1538-7445.Am2018-4839  0.429
2017 Nakamura T, Okabe S, Yoshida H, Iida K, Ma Y, Sasaki S, Yamori T, Shin-Ya K, Nakano I, Nagasawa K, Seimiya H. Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole. Scientific Reports. 7: 3605. PMID 28620243 DOI: 10.1038/S41598-017-03785-8  0.413
2017 Mashima T, Taneda Y, Jang MK, Mizutani A, Muramatsu Y, Yoshida H, Sato A, Tanaka N, Sugimoto Y, Seimiya H. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Oncotarget. PMID 28615517 DOI: 10.18632/Oncotarget.18146  0.388
2017 Migita T, Ueda A, Ohishi T, Hatano M, Seimiya H, Horiguchi SI, Koga F, Shibasaki F. Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 28240746 DOI: 10.1038/Labinvest.2017.17  0.387
2017 Ohishi T, Yoshida H, Katori M, Migita T, Muramatsu Y, Miyake M, Ishikawa Y, Saiura A, Iemura SI, Natsume T, Seimiya H. Tankyrase-binding protein TNKS1BP1 regulates actin cytoskeleton rearrangement and cancer cell invasion. Cancer Research. PMID 28202517 DOI: 10.1158/0008-5472.Can-16-1846  0.413
2017 Tanaka N, Mashima T, Mizutani A, Sato A, Aoyama A, Gong B, Yoshida H, Muramatsu Y, Nakata K, Matsuura M, Katayama R, Nagayama S, Fujita N, Sugimoto Y, Seimiya H. APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer. Molecular Cancer Therapeutics. PMID 28179481 DOI: 10.1158/1535-7163.Mct-16-0578  0.363
2017 Ohishi T, Yoshida H, Katori M, Migita T, Muramatsu Y, Miyake M, Ishikawa Y, Saiura A, Iemura S, Natsume T, Seimiya H. Abstract 1882: Tankyrase-binding protein TNKS1BP1 regulates cancer cell invasion Cancer Research. 77: 1882-1882. DOI: 10.1158/1538-7445.Am2017-1882  0.396
2016 Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, et al. Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. Cancer Science. 107: 189-202. PMID 26919617 DOI: 10.1111/Cas.12857  0.342
2016 Hasegawa D, Okabe S, Okamoto K, Nakano I, Shin-Ya K, Seimiya H. G-quadruplex ligand-induced DNA damage response coupled with telomere dysfunction and replication stress in glioma stem cells. Biochemical and Biophysical Research Communications. PMID 26845351 DOI: 10.1016/J.Bbrc.2016.01.176  0.407
2016 Ouchi R, Okabe S, Migita T, Nakano I, Seimiya H. Senescence from glioma stem cell differentiation promotes tumor growth. Biochemical and Biophysical Research Communications. PMID 26775840 DOI: 10.1016/J.Bbrc.2016.01.071  0.344
2015 Mizutani A, Koinuma D, Seimiya H, Miyazono K. The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma. Oncogene. PMID 26522722 DOI: 10.1038/Onc.2015.412  0.376
2015 Seimiya H. Predicting Risk at the End of the End: Telomere G-tail as a Biomarker. Ebiomedicine. 2: 802-3. PMID 26425685 DOI: 10.1016/J.Ebiom.2015.07.006  0.342
2015 Mashima T, Ushijima M, Matsuura M, Tsukahara S, Kunimasa K, Furuno A, Saito S, Kitamura M, Soma-Nagae T, Seimiya H, Dan S, Yamori T, Tomida A. Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation. Cancer Science. 106: 909-20. PMID 25911996 DOI: 10.1111/Cas.12682  0.308
2015 Hirashima K, Seimiya H. Telomeric repeat-containing RNA/G-quadruplex-forming sequences cause genome-wide alteration of gene expression in human cancer cells in vivo. Nucleic Acids Research. 43: 2022-32. PMID 25653161 DOI: 10.1093/Nar/Gkv063  0.437
2015 Hirashima K, Seimiya H. Abstract 3870: Telomeric non-coding RNA causes genome-wide alteration of gene expression in cancer Cancer Research. 75: 3870-3870. DOI: 10.1158/1538-7445.Am2015-3870  0.45
2015 Mizutani A, Koinuma D, Seimiya H, Miyazono K. Abstract 2131: The Arkadia-ESRP2 axis suppresses tumor progression: Analyses in clear cell renal cell carcinoma Cancer Research. 75: 2131-2131. DOI: 10.1158/1538-7445.Am2015-2131  0.302
2014 Shimamoto A, Kagawa H, Zensho K, Sera Y, Kazuki Y, Osaki M, Oshimura M, Ishigaki Y, Hamasaki K, Kodama Y, Yuasa S, Fukuda K, Hirashima K, Seimiya H, Koyama H, et al. Reprogramming suppresses premature senescence phenotypes of Werner syndrome cells and maintains chromosomal stability over long-term culture. Plos One. 9: e112900. PMID 25390333 DOI: 10.1371/Journal.Pone.0112900  0.372
2014 Mashima T, Soma-Nagae T, Migita T, Kinoshita R, Iwamoto A, Yuasa T, Yonese J, Ishikawa Y, Seimiya H. TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression. Cancer Research. 74: 4888-97. PMID 24962028 DOI: 10.1158/0008-5472.Can-13-3718  0.355
2014 Ohishi T, Muramatsu Y, Yoshida H, Seimiya H. TRF1 ensures the centromeric function of Aurora-B and proper chromosome segregation. Molecular and Cellular Biology. 34: 2464-78. PMID 24752893 DOI: 10.1128/Mcb.00161-14  0.375
2014 Migita T, Okabe S, Ikeda K, Igarashi S, Sugawara S, Tomida A, Soga T, Taguchi R, Seimiya H. Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells. International Journal of Cancer. Journal International Du Cancer. 135: 37-47. PMID 24310723 DOI: 10.1002/Ijc.28652  0.303
2014 Mashima T, Soma-Nagae T, Migita T, Kinoshita R, Iwamoto A, Yuasa T, Yonese J, Ishikawa Y, Seimiya H. Abstract LB-51: TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival via the regulation of endoplasmic reticulum chaperone expression Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-51  0.371
2013 Hirashima K, Migita T, Sato S, Muramatsu Y, Ishikawa Y, Seimiya H. Telomere length influences cancer cell differentiation in vivo. Molecular and Cellular Biology. 33: 2988-95. PMID 23716593 DOI: 10.1128/Mcb.00136-13  0.467
2013 Iida K, Majima S, Nakamura T, Seimiya H, Nagasawa K. Evaluation of the interaction between long telomeric DNA and macrocyclic hexaoxazole (6OTD) dimer of a G-quadruplex ligand. Molecules (Basel, Switzerland). 18: 4328-41. PMID 23584054 DOI: 10.3390/Molecules18044328  0.309
2013 Migita T, Okabe S, Ikeda K, Igarashi S, Sugawara S, Tomida A, Taguchi R, Soga T, Seimiya H. Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact. The American Journal of Pathology. 182: 1800-10. PMID 23506848 DOI: 10.1016/J.Ajpath.2013.01.048  0.366
2013 Iida K, Tsubouchi G, Nakamura T, Majima S, Seimiya H, Nagasawa K. Interaction of long telomeric DNAs with macrocyclic hexaoxazole as a G-quadruplex ligand Medchemcomm. 4: 260-264. DOI: 10.1039/C2Md20234D  0.311
2012 Kawahara T, Hosoya T, Tsukamoto M, Okabe S, Yamamura H, Hayakawa M, Seimiya H, Takagi M, Shin-Ya K. JBIR-120: a new growth inhibitor of hormone-refractory prostate cancer cells. The Journal of Antibiotics. 65: 373-5. PMID 22534652 DOI: 10.1038/Ja.2012.32  0.324
2012 Miyazaki T, Pan Y, Joshi K, Purohit D, Hu B, Demir H, Mazumder S, Okabe S, Yamori T, Viapiano M, Shin-ya K, Seimiya H, Nakano I. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1268-80. PMID 22230766 DOI: 10.1158/1078-0432.Ccr-11-1795  0.367
2011 Takahashi K, Imano R, Kibe T, Seimiya H, Muramatsu Y, Kawabata N, Tanaka G, Matsumoto Y, Hiromoto T, Koizumi Y, Nakazawa N, Yanagida M, Yukawa M, Tsuchiya E, Ueno M. Fission yeast Pot1 and RecQ helicase are required for efficient chromosome segregation. Molecular and Cellular Biology. 31: 495-506. PMID 21098121 DOI: 10.1128/Mcb.00613-10  0.332
2011 Miyazaki T, Pan Y, Hu B, Demir H, Joshi K, Okabe S, Yamori T, Viapiano M, Shin-ya K, Seimiya H, Nakano I. Abstract 3302: The effects of the g-quadruplex ligand telomestatin to human brain tumor stem cell survival and growth Cancer Research. 71: 3302-3302. DOI: 10.1158/1538-7445.Am2011-3302  0.397
2010 Mashima T, Okabe S, Seimiya H. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth. Molecular Pharmacology. 78: 846-54. PMID 20709811 DOI: 10.1124/Mol.110.064790  0.37
2010 Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D, Nakata H, Tohyama S, Hashimoto H, Kodaira M, Okada Y, Seimiya H, Fusaki N, Hasegawa M, Fukuda K. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 7: 11-4. PMID 20621043 DOI: 10.1016/J.Stem.2010.06.003  0.308
2010 Yashiroda Y, Okamoto R, Hatsugai K, Takemoto Y, Goshima N, Saito T, Hamamoto M, Sugimoto Y, Osada H, Seimiya H, Yoshida M. A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor. Biochemical and Biophysical Research Communications. 394: 569-73. PMID 20214890 DOI: 10.1016/J.Bbrc.2010.03.021  0.376
2010 Ohishi T, Hirota T, Tsuruo T, Seimiya H. TRF1 mediates mitotic abnormalities induced by Aurora-A overexpression. Cancer Research. 70: 2041-52. PMID 20160025 DOI: 10.1158/0008-5472.Can-09-2008  0.375
2010 Migita T, Narita T, Asaka R, Miyagi E, Nagano H, Nomura K, Matsuura M, Satoh Y, Okumura S, Nakagawa K, Seimiya H, Ishikawa Y. Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. The American Journal of Pathology. 176: 1756-66. PMID 20150439 DOI: 10.2353/Ajpath.2010.090500  0.327
2010 Kobayashi Y, Sato K, Kibe T, Seimiya H, Nakamura A, Yukawa M, Tsuchiya E, Ueno M. Expression of mutant RPA in human cancer cells causes telomere shortening. Bioscience, Biotechnology, and Biochemistry. 74: 382-5. PMID 20139621 DOI: 10.1271/Bbb.90496  0.428
2009 Mashima T, Sato S, Okabe S, Miyata S, Matsuura M, Sugimoto Y, Tsuruo T, Seimiya H. Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide. Cancer Science. 100: 1556-62. PMID 19459852 DOI: 10.1111/J.1349-7006.2009.01203.X  0.398
2009 Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. British Journal of Cancer. 100: 1369-72. PMID 19352381 DOI: 10.1038/Sj.Bjc.6605007  0.33
2009 McCabe N, Cerone MA, Ohishi T, Seimiya H, Lord CJ, Ashworth A. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene. 28: 1465-70. PMID 19182824 DOI: 10.1038/Onc.2008.483  0.383
2009 Mashima T, Sato S, Sugimoto Y, Tsuruo T, Seimiya H. Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions. Oncogene. 28: 9-19. PMID 18806831 DOI: 10.1038/Onc.2008.355  0.382
2008 Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Research. 68: 8547-54. PMID 18922930 DOI: 10.1158/0008-5472.Can-08-1235  0.402
2008 Muramatsu Y, Tahara H, Ono T, Tsuruo T, Seimiya H. Telomere elongation by a mutant tankyrase 1 without TRF1 poly(ADP-ribosyl)ation. Experimental Cell Research. 314: 1115-24. PMID 18221737 DOI: 10.1016/J.Yexcr.2007.12.005  0.338
2007 Ohishi T, Tsuruo T, Seimiya H. Evaluation of tankyrase inhibition in whole cells. Methods in Molecular Biology (Clifton, N.J.). 405: 133-46. PMID 18369822 DOI: 10.1007/978-1-60327-070-0_11  0.449
2007 Tanaka E, Fukuda H, Nakashima K, Tsuchiya N, Seimiya H, Nakagama H. HnRNP A3 binds to and protects mammalian telomeric repeats in vitro. Biochemical and Biophysical Research Communications. 358: 608-14. PMID 17502110 DOI: 10.1016/J.Bbrc.2007.04.177  0.313
2007 Muramatsu Y, Ohishi T, Sakamoto M, Tsuruo T, Seimiya H. Cross-species difference in telomeric function of tankyrase 1. Cancer Science. 98: 850-7. PMID 17433040 DOI: 10.1111/J.1349-7006.2007.00462.X  0.376
2006 Seimiya H. The telomeric PARP, tankyrases, as targets for cancer therapy. British Journal of Cancer. 94: 341-5. PMID 16421589 DOI: 10.1038/Sj.Bjc.6602951  0.432
2006 Tahara H, Shin-Ya K, Seimiya H, Yamada H, Tsuruo T, Ide T. G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells. Oncogene. 25: 1955-66. PMID 16302000 DOI: 10.1038/Sj.Onc.1209217  0.485
2006 Tahara H, Seimiya H, Shin-ya K, Ide T. 627 POSTER New screening technology for development of effective anti-cancer drugs targeting telomere G-tail Ejc Supplements. 4: 189. DOI: 10.1016/S1359-6349(06)70632-2  0.33
2005 Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell. 7: 25-37. PMID 15652747 DOI: 10.1016/J.Ccr.2004.11.021  0.419
2004 Motiwala T, Kutay H, Ghoshal K, Bai S, Seimiya H, Tsuruo T, Suster S, Morrison C, Jacob ST. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 101: 13844-9. PMID 15356345 DOI: 10.1073/Pnas.0405451101  0.372
2004 Seimiya H, Muramatsu Y, Smith S, Tsuruo T. Functional subdomain in the ankyrin domain of tankyrase 1 required for poly(ADP-ribosyl)ation of TRF1 and telomere elongation. Molecular and Cellular Biology. 24: 1944-55. PMID 14966275 DOI: 10.1128/Mcb.24.5.1944-1955.2004  0.451
2002 Seimiya H, Smith S. The telomeric poly(ADP-ribose) polymerase, tankyrase 1, contains multiple binding sites for telomeric repeat binding factor 1 (TRF1) and a novel acceptor, 182-kDa tankyrase-binding protein (TAB182). The Journal of Biological Chemistry. 277: 14116-26. PMID 11854288 DOI: 10.1074/Jbc.M112266200  0.467
2001 Wang Z, Bhattacharya N, Meyer MK, Seimiya H, Tsuruo T, Tonani JA, Magnuson NS. Pim-1 negatively regulates the activity of PTP-U2S phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cells. Archives of Biochemistry and Biophysics. 390: 9-18. PMID 11368509 DOI: 10.1006/Abbi.2001.2370  0.327
2000 Seimiya H, Sawada H, Muramatsu Y, Shimizu M, Ohko K, Yamane K, Tsuruo T. Involvement of 14-3-3 proteins in nuclear localization of telomerase. The Embo Journal. 19: 2652-61. PMID 10835362 DOI: 10.1093/Emboj/19.11.2652  0.388
1999 Seimiya H, Tanji M, Oh-hara T, Tomida A, Naasani I, Tsuruo T. Hypoxia up-regulates telomerase activity via mitogen-activated protein kinase signaling in human solid tumor cells. Biochemical and Biophysical Research Communications. 260: 365-70. PMID 10403776 DOI: 10.1006/Bbrc.1999.0910  0.39
1999 Dan S, Naito M, Seimiya H, Kizaki A, Mashima T, Tsuruo T. Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells. Oncogene. 18: 1277-83. PMID 10022809 DOI: 10.1038/Sj.Onc.1202423  0.325
1999 Chen Z, Seimiya H, Naito M, Mashima T, Kizaki A, Dan S, Imaizumi M, Ichijo H, Miyazono K, Tsuruo T. ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene. 18: 173-80. PMID 9926932 DOI: 10.1038/Sj.Onc.1202276  0.301
1998 Mashima T, Seimiya H, Chen Z, Kataoka S, Tsuruo T. Apoptosis resistance in tumor cells. Cytotechnology. 27: 293-308. PMID 19002800 DOI: 10.1023/A:1008058031511  0.35
1998 Naasani I, Seimiya H, Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochemical and Biophysical Research Communications. 249: 391-6. PMID 9712707 DOI: 10.1006/Bbrc.1998.9075  0.453
1998 Seimiya H, Tsuruo T. Functional involvement of PTP-U2L in apoptosis subsequent to terminal differentiation of monoblastoid leukemia cells. The Journal of Biological Chemistry. 273: 21187-93. PMID 9694875 DOI: 10.1074/Jbc.273.33.21187  0.374
1998 Seimiya H, Tsuruo T. [Telomerase downregulation during differentiation of leukemia cells]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 56: 1121-5. PMID 9613107  0.314
1998 Haga N, Naito M, Seimiya H, Tomida A, Dong J, Tsuruo T. 2-Deoxyglucose inhibits chemotherapeutic drug-induced apoptosis in human monocytic leukemia U937 cells with inhibition of c-Jun N-terminal kinase 1/stress-activated protein kinase activation. International Journal of Cancer. Journal International Du Cancer. 76: 86-90. PMID 9533766 DOI: 10.1002/(Sici)1097-0215(19980330)76:1<86::Aid-Ijc14>3.0.Co;2-E  0.356
1997 Seimiya H, Mashima T, Toho M, Tsuruo T. c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. The Journal of Biological Chemistry. 272: 4631-6. PMID 9020192 DOI: 10.1074/Jbc.272.7.4631  0.362
1995 Yamaki H, Nakajima M, Seimiya H, Saya H, Sugita M, Tsuruo T. Inhibition of the association with nuclear matrix of pRB, p70 and p40 proteins along with the specific suppression of c-MYC expression by geldanamycin, an inhibitor of Src tyrosine kinase. The Journal of Antibiotics. 48: 1021-6. PMID 7592047 DOI: 10.7164/Antibiotics.48.1021  0.339
1993 Heike Y, Sone S, Yano S, Seimiya H, Tsuruo T, Ogura T. M-CSF gene transduction in multidrug-resistant human cancer cells to enhance anti-P-glycoprotein antibody-dependent macrophage-mediated cytotoxicity. International Journal of Cancer. Journal International Du Cancer. 54: 851-7. PMID 8100809 DOI: 10.1002/Ijc.2910540521  0.368
1993 Noguchi K, Naito M, Tezuka K, Ishii S, Seimiya H, Sugimoto Y, Amann E, Tsuruo T. cDNA expression cloning of the 85-kDa protein overexpressed in adriamycin-resistant cells. Biochemical and Biophysical Research Communications. 192: 88-95. PMID 7682812 DOI: 10.1006/Bbrc.1993.1385  0.336
1992 Ariyoshi K, Hamada H, Naito M, Heike Y, Seimiya H, Maezawa K, Tsuruo T. Mouse-human chimeric antibody MH171 against the multidrug transporter P-glycoprotein. Japanese Journal of Cancer Research : Gann. 83: 515-21. PMID 1352281 DOI: 10.1111/J.1349-7006.1992.Tb01958.X  0.308
Low-probability matches (unlikely to be authored by this person)
2018 Ma Y, Tsushima Y, Sakuma M, Sasaki S, Iida K, Okabe S, Seimiya H, Hirokawa T, Nagasawa K. Development of G-quadruplex ligands for selective induction of a parallel-type topology. Organic & Biomolecular Chemistry. PMID 30187070 DOI: 10.1039/C8Ob01702F  0.298
2018 Takahari D, Wakatsuki T, Mashima T, Chin K, Ichimura T, Ogura M, Matsushima T, Osumi H, Nakayama I, Ota Y, Shinozaki E, Suenaga M, Kawata N, Horiike Y, Seimiya H, et al. Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer. Journal of Clinical Oncology. 36: 81-81. DOI: 10.1200/Jco.2018.36.4_Suppl.81  0.295
2010 Hatsugai K, Ohishi T, Sugimoto Y, Seimiya H. Tankyrase-1 assembly to large protein complexes blocks its telomeric function. Febs Letters. 584: 3885-90. PMID 20696165 DOI: 10.1016/J.Febslet.2010.07.062  0.291
2020 Koi H, Takahashi N, Fuchi Y, Umeno T, Muramatsu Y, Seimiya H, Karasawa S, Oguri H. A fully synthetic 6-aza-artemisinin bearing an amphiphilic chain generates aggregates and exhibits anti-cancer activities. Organic & Biomolecular Chemistry. 18: 5339-5343. PMID 32618320 DOI: 10.1039/D0Ob00919A  0.287
2002 Seimiya H, Oh-hara T, Suzuki T, Naasani I, Shimazaki T, Tsuchiya K, Tsuruo T. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Molecular Cancer Therapeutics. 1: 657-65. PMID 12479362  0.287
2015 Tera M, Hirokawa T, Okabe S, Sugahara K, Seimiya H, Shimamoto K. Design and Synthesis of a Berberine Dimer: A Fluorescent Ligand with High Affinity towards G-Quadruplexes. Chemistry (Weinheim An Der Bergstrasse, Germany). 21: 14519-28. PMID 26272465 DOI: 10.1002/Chem.201501693  0.286
2013 Kim EG, Seimiya H, Chung J, Hoheisel J, Lim IK, Fujiki H, Park SC. The eleventh Korea-Japan-Germany joint symposium on cancer and ageing research. Journal of Cancer Research and Clinical Oncology. 139: 901-4. PMID 23455879 DOI: 10.1007/S00432-013-1397-1  0.281
2010 Tera M, Iida K, Ikebukuro K, Seimiya H, Shin-Ya K, Nagasawa K. Visualization of G-quadruplexes by using a BODIPY-labeled macrocyclic heptaoxazole. Organic & Biomolecular Chemistry. 8: 2749-55. PMID 20414484 DOI: 10.1039/C002117B  0.278
2013 Ushijima M, Mashima T, Tomida A, Dan S, Saito S, Furuno A, Tsukahara S, Seimiya H, Yamori T, Matsuura M. Development of a gene expression database and related analysis programs for evaluation of anticancer compounds. Cancer Science. 104: 360-8. PMID 23176546 DOI: 10.1111/Cas.12071  0.277
2016 Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget. PMID 27166185 DOI: 10.18632/Oncotarget.9187  0.276
2022 Moyret-Lalle C, Prodhomme MK, Burlet D, Kashiwagi A, Petrilli V, Puisieux A, Seimiya H, Tissier A. Role of EMT in the DNA damage response, double-strand break repair pathway choice and its implications in cancer treatment. Cancer Science. PMID 35534984 DOI: 10.1111/cas.15389  0.274
2012 Nakamura T, Iida K, Tera M, Shin-ya K, Seimiya H, Nagasawa K. A caged ligand for a telomeric G-quadruplex. Chembiochem : a European Journal of Chemical Biology. 13: 774-7. PMID 22438312 DOI: 10.1002/Cbic.201200013  0.273
2024 Morino S, Mashima T, Shirai F, Nagayama S, Katayama R, Seimiya H. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer. Cancer Letters. 584: 216632. PMID 38216082 DOI: 10.1016/j.canlet.2024.216632  0.272
1993 Seimiya H, Naito M, Mashima T, Yasui H, Kuwana Y, Kurosawa Y, Tsuruo T. T cell receptor-extracellular constant regions as hetero-cross-linkers for immunoglobulin variable regions. Journal of Biochemistry. 113: 687-91. PMID 8370665 DOI: 10.1093/Oxfordjournals.Jbchem.A124104  0.271
2017 Takahari D, Wakatsuki T, Mashima T, Ichimura T, Chin K, Ogura M, Nakayama I, Matsushima T, Osumi H, Ozaka M, Suenaga M, Shinozaki E, Seimiya H, Fujita N, Yamaguchi K. Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer: Preliminary results. Journal of Clinical Oncology. 35: 72-72. DOI: 10.1200/Jco.2017.35.4_Suppl.72  0.27
1995 Seimiya H, Sawabe T, Toho M, Tsuruo T. Phorbol ester-resistant monoblastoid leukemia cells with a functional mitogen-activated protein kinase cascade but without responsive protein tyrosine phosphatases. Oncogene. 11: 2047-54. PMID 7478524  0.267
2012 Deardorff MA, Bando M, Nakato R, Watrin E, Itoh T, Minamino M, Saitoh K, Komata M, Katou Y, Clark D, Cole KE, De Baere E, Decroos C, Di Donato N, Ernst S, ... ... Seimiya H, et al. HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature. 489: 313-7. PMID 22885700 DOI: 10.1038/Nature11316  0.264
2018 Ota Y, Wakatsuki T, Mashima T, Takahari D, Chin K, Ichimura T, Ogura M, Matsushima T, Osumi H, Nakayama I, Shinozaki E, Suenaga M, Kawata N, Horiike Y, Seimiya H, et al. Plasma biomarker dynamics following ramucirumab treatment and survival analysis after ramucirumab treatment failure in patients with advanced gastric cancer. Journal of Clinical Oncology. 36: 79-79. DOI: 10.1200/Jco.2018.36.4_Suppl.79  0.264
2019 Sueoka E, Watanabe T, Mashima T, Shirakami Y, Komori A, Matsuo K, Yoshikawa HY, Cho KA, Park TJ, Seimiya H, Kim EG, Suganuma M, Chung J. Meeting report of the 14th Japan-Korea joint symposium on cancer and aging research: current status of translational research and approaches to precision medicine. Journal of Cancer Research and Clinical Oncology. PMID 30859317 DOI: 10.1007/S00432-019-02887-2  0.263
2019 Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz HJ. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Cancer Science. PMID 31821662 DOI: 10.1111/Cas.14273  0.262
2015 Seimiya H. [Cancer therapy by PARP inhibitors]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 73: 1330-5. PMID 26281686  0.26
2020 Matsumoto K, Okamoto K, Okabe S, Fujii R, Ueda K, Ohashi K, Seimiya H. G-quadruplex-forming nucleic acids interact with SF3B2 and suppress innate immune gene expression. Genes to Cells : Devoted to Molecular & Cellular Mechanisms. PMID 33290632 DOI: 10.1111/gtc.12824  0.257
2012 Ha GH, Kim HS, Go H, Lee H, Seimiya H, Chung DH, Lee CW. Tankyrase-1 function at telomeres and during mitosis is regulated by Polo-like kinase-1-mediated phosphorylation. Cell Death and Differentiation. 19: 321-32. PMID 21818122 DOI: 10.1038/cdd.2011.101  0.254
2018 Hatta T, Iemura SI, Ohishi T, Nakayama H, Seimiya H, Yasuda T, Iizuka K, Fukuda M, Takeda J, Natsume T, Horikawa Y. Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B. Scientific Reports. 8: 16756. PMID 30425305 DOI: 10.1038/S41598-018-35204-X  0.249
1993 Seimiya H, Tsuruo T. Differential expression of protein tyrosine phosphatase genes during phorbol ester-induced differentiation of human leukemia U937 cells. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 4: 1033-9. PMID 8117617  0.236
2019 Suenaga M, Wakatsuki T, Mashima T, Ogura M, Ichimura T, Shinozaki E, Nakayama I, Osumi H, Ota Y, Takahari D, Chin K, Seimiya H, Yamaguchi K. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. Investigational New Drugs. PMID 30838483 DOI: 10.1007/S10637-019-00749-9  0.235
2021 Miyata K, Imai Y, Hori S, Nishio M, Loo TM, Okada R, Yang L, Nakadai T, Maruyama R, Fujii R, Ueda K, Jiang L, Zheng H, Toyokuni S, Sakata T, ... ... Seimiya H, et al. Pericentromeric noncoding RNA changes DNA binding of CTCF and inflammatory gene expression in senescence and cancer. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34426493 DOI: 10.1073/pnas.2025647118  0.235
2020 Yasuda M, Ma Y, Okabe S, Wakabayashi Y, Su D, Chang YT, Seimiya H, Tera M, Nagasawa K. Target identification of a macrocyclic hexaoxazole G-quadruplex ligand using post-target-binding visualization. Chemical Communications (Cambridge, England). PMID 33030187 DOI: 10.1039/d0cc04957c  0.22
2016 Seimiya H. Recent advances in telomere biology for new cancer medicine Annals of Oncology. 27: vii70. DOI: 10.1093/annonc/mdw515  0.219
2019 Mizutani A, Seimiya H. Tankyrase promotes primary precursor miRNA processing to precursor miRNA. Biochemical and Biophysical Research Communications. PMID 31806370 DOI: 10.1016/J.Bbrc.2019.11.191  0.214
2023 Chiba M, Miyata K, Okawa H, Tanaka Y, Ueda K, Seimiya H, Takahashi A. YBX1 Regulates Satellite II RNA Loading into Small Extracellular Vesicles and Promotes the Senescent Phenotype. International Journal of Molecular Sciences. 24. PMID 38003589 DOI: 10.3390/ijms242216399  0.21
2006 Seimiya H. Cancer therapy targeting the telomere maintenance system Drug Delivery System. 21: 24-31. DOI: 10.2745/DDS.21.24  0.206
2023 Chen M, Mashima T, Oishi T, Muramatsu Y, Seto Y, Takamatsu M, Kawata N, Morino S, Nakamura A, Inaba S, Yuan X, Maruyama K, Suzuki M, Sato A, Yoshida H, ... ... Seimiya H, et al. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. British Journal of Cancer. PMID 37968472 DOI: 10.1038/s41416-023-02484-8  0.203
1998 Seimiya H, Tsuruo T. [Involvement of PTP-U2 in terminal differentiation and apoptosis of leukemia cells]. Tanpakushitsu Kakusan Koso. Protein, Nucleic Acid, Enzyme. 43: 1153-61. PMID 9655974  0.202
1995 Hanaoka K, Fujita N, Lee SH, Seimiya H, Naito M, Tsuruo T. Involvement of CD45 in adhesion and suppression of apoptosis of mouse malignant T-lymphoma cells. Cancer Research. 55: 2186-90. PMID 7743522  0.193
2024 Hirose S, Mashima T, Yuan X, Yamashita M, Kitano S, Torii S, Migita T, Seimiya H. Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8 T cell infiltration in melanoma. Cancer Science. PMID 38258342 DOI: 10.1111/cas.16073  0.192
1995 Seimiya H, Sawabe T, Inazawa J, Tsuruo T. Cloning, expression and chromosomal localization of a novel gene for protein tyrosine phosphatase (PTP-U2) induced by various differentiation-inducing agents. Oncogene. 10: 1731-8. PMID 7753550  0.189
1999 Naasani I, Seimiya H, Yamori T, Tsuruo T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Research. 59: 4004-11. PMID 10463599  0.175
2020 Shimizu T, Takahashi N, Huber VJ, Asawa Y, Ueda H, Yoshimori A, Muramatsu Y, Seimiya H, Kouji H, Nakamura H, Oguri H. Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibitory activities of hypoxia-inducible factor 1α. Bioorganic & Medicinal Chemistry. 30: 115949. PMID 33360196 DOI: 10.1016/j.bmc.2020.115949  0.167
2014 Takahashi K, Imano R, Kibe T, Seimiya H, Muramatsu Y, Kawabata N, Tanaka G, Matsumoto Y, Hiromoto T, Koizumi Y, Nakazawa N, Yanagida M, Yukawa M, Tsuchiya E, Ueno M. Correction to Fission yeast Pot1 and RecQ helicase are required for efficient chromosome segregation [Mol. Cell. Biol. Volume 31, no. 3, p. 495-506, 2011.] Molecular and Cellular Biology. 34: 2551-2552. DOI: 10.1128/MCB.00506-14  0.165
2023 Mezawa Y, Wang T, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Yang L, Maruyama R, Seimiya H, Orimo A. Glutamine deficiency drives transforming growth factor-β signaling activation that gives rise to myofibroblastic carcinoma-associated fibroblasts. Cancer Science. 114: 4376-4387. PMID 37706357 DOI: 10.1111/cas.15955  0.165
2021 Mashima T, Wakatsuki T, Kawata N, Jang MK, Nagamori A, Yoshida H, Nakamura K, Migita T, Seimiya H, Yamaguchi K. Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo. Scientific Reports. 11: 15125. PMID 34302038 DOI: 10.1038/s41598-021-94584-9  0.163
1995 Dong J, Naito M, Tatsuta T, Seimiya H, Johdo O, Tsuruo T. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Oncology Research. 7: 245-52. PMID 8534930  0.161
2020 Tanji K, Mori F, Shirai F, Fukami T, Seimiya H, Utsumi J, Kakita A, Wakabayashi K. Novel tankyrase inhibitors suppress TDP-43 aggregate formation. Biochemical and Biophysical Research Communications. 537: 85-92. PMID 33387887 DOI: 10.1016/j.bbrc.2020.12.037  0.158
2021 Nishiya N, Oku Y, Ishikawa C, Fukuda T, Dan S, Mashima T, Ushijima M, Furukawa Y, Sasaki Y, Otsu K, Sakyo T, Abe M, Yonezawa H, Ishibashi F, Matsuura M, ... ... Seimiya H, et al. Lamellarin 14, a Derivative of Marine Alkaloids, Inhibits the T790M/C797S Mutant Epidermal Growth Factor Receptor. Cancer Science. PMID 33544933 DOI: 10.1111/cas.14839  0.15
2011 Mashima T, Okabe S, Seimiya H. Molecular Pharmacological approach reveals potential new strategies to suppress androgen receptor signaling in prostate cancer Molecular and Cellular Pharmacology. 3: 7-12. DOI: 10.4255/mcpharmacol.11.02  0.148
2015 Tera M, Hirokawa T, Okabe S, Sugahara K, Seimiya H, Shimamoto K. Design and Synthesis of a Berberine Dimer: A Fluorescent Ligand with High Affinity towards G-Quadruplexes Chemistry - a European Journal. DOI: 10.1002/chem.201501693  0.104
2014 Miyagawa M, Satou T, Yukimune C, Ishibashi A, Seimiya H, Yamada H, Hasegawa T, Koike K. Anxiolytic-like effect of Illicium verum fruit oil, trans-anethole and related compounds in mice. Phytotherapy Research : Ptr. 28: 1710-2. PMID 24919985 DOI: 10.1002/ptr.5190  0.043
2014 Hasegaw T, Seimiya H, Fujihara T, Fujiwara N, Yamada H. Aroma profile of star anise and the structure-odor relationship of anethole. Natural Product Communications. 9: 251-6. PMID 24689303  0.034
2014 Satou T, Miyagawa M, Seimiya H, Yamada H, Hasegawa T, Koike K. Prolonged anxiolytic-like activity of sandalwood (Santalum album L.) oil in stress-loaded mice Flavour and Fragrance Journal. 29: 35-38. DOI: 10.1002/ffj.3176  0.033
1966 Ishikawa S, Masuda S, Ono M, Seimiya H, Itaya H. [Effect of N-acetyl-L-cysteine injection as a premedication for bronchography]. Kyobu Geka. the Japanese Journal of Thoracic Surgery. 19: 47-54. PMID 6010451  0.019
Hide low-probability matches.